Studies have shown that altered glutamate signaling and oxidative stress are key contributors to impaired cortical function and loss of inhibitory control that are reported to underlie various CNS conditions such as obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders.
Watch a Video
At Promentis, our goal is to leverage our team’s extensive experience in the CNS space to develop an innovative therapeutic platform capable of restoring inhibitory control by targeting a unique brain mechanism known to modulate glutamatergic neurotransmission and oxidative stress.
Promentis is currently focused on advancing SXC-2023 and other small molecules designed to target System xc-, a promising therapeutic target capable of restoring impaired glutamate signaling in the brain. System xc– is broadly expressed on astrocytes and functions to exchange extracellular cystine for intracellular glutamate.
Promentis believes this approach takes broader account of the dysfunction within the glutamatergic system and has the potential to restore imbalances in inhibitory control associated with various neuropsychiatric disorders, including obsessive-complusive, substance-related and addictive disorders. Thus, Promentis is embarking on an effort to REDEFINE WHAT IS POSSIBLE® in the treatment of such conditions.
Promentis’ first neuropsychiatric indication is trichotillomania, a disabling and underrecognized condition characterized by a loss of inhibitory control that manifests itself as recurrent hair pulling, leading to noticeable hair loss and substantial adverse impact on quality of life, health and employment. Click here to read more about trichotillomania.
Working across a broad range of structures and approaches, Promentis has developed a portfolio of compounds designed to act on System xc– .Promentis has strong composition-of-matter protection covering its lead compounds and a broad patent estate covering a wide variety of different approaches and structures related to the company’s program.
Pioneering the discovery & development of therapeutics targeting glutamatergic imbalances and oxidative stress